Skip to content
drillr.ai
Sign up

AMPH

Amphastar Pharmaceuticals, Inc.

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US

$23.18
−2.77%
Ask drillr

  • Aug 6, 2026, 23:04 UTC

    Amphastar Pharmaceuticals is addressing an FDA warning letter at its IMS subsidiary.

    Source:

  • Aug 6, 2026, 20:05 UTC

    Amphastar Pharmaceuticals reported financial results for the three months ended June 30, 2026, with net revenues of $183.9 million, GAAP net income of $30.3 million, and adjusted non-GAAP net income of $40.8 million.

    Source:

  • Jul 13, 2026, 00:00 UTC

    Amphastar Pharmaceuticals appointed Anthony Pierce as a Class III director, effective July 9, 2026.